Good to see more articles  like this appearing.

This one is published by Third Wave..

Here’s the introduction

That’s if things go well, of course. In all of this promising progress, there are some concerning developments, too—and not just of the legal or political variety. While fears that the US government could shut down research yet again are still valid, a deeper and more insidious threat is brewing on the opposite end of the spectrum: as psychedelics go mainstream, capitalism is swiftly swooping in. That could kill the promise of the psychedelic awakening before it’s even had time to stand up and stretch its legs.

Consider, for instance, these recent Big Money developments. After receiving FDA approval for the use of psilocybin in clinical trials for treatment-resistant depression, the Peter Thiel-backed private company Compass Pathways (which many fear is establishing a monopoly on psilocybin-assisted psychotherapy) became the first psychedelics company to go public on a big US exchange—and its market cap surged to $1 billion on its first day. Meanwhile, Big Pharma corporations Johnson & Johnson and AbbVie have jumped into the ketamine game, and Robert Mercer, who funded Donald Trump’s 2016 campaign as well as right-wing propaganda machine Breitbart, gifted MAPS a $1 million grant for research into PTSD treatments for veterans. With all this action—and much, much more—many in the big business world are projecting that the psychedelic market could be worth nearly $7 billion by 2027. For investors, that means psychedelics are increasingly looking like the next big opportunity.

On the one hand, this is good news, right? If mainstream corporations and entities get on board, then don’t we get what we all want—widespread psychedelic healing for all?

Not exactly.

More at